DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sarcopenia Forecast in 13 Major Markets 2016-2026" report to their offering.
Patients with sarcopenia have an increased risk of adverse outcomes such as physical disability, poorer quality of life, hospitalisation and mortality.
This report provides the current prevalent population for Sarcopenia across 13 Major Markets (USA, France, Canada, Germany, Italy, Spain, Brazil, India, UK, Australia, Japan, Korea and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Sarcopenia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Diseases associated with sarcopenia:
- Obesity
- Type 2 diabetes
- Metabolic syndrome and insulin resistance
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Co-morbid Conditions/Features Associated with the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Sarcopenia
10. Features of Sarcopenia Patients
11. Abbreviations used in the Report
12. Patient-Based Offering
13. Online Pricing Data and Platforms
14. References
15. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/q5mwkz/sarcopenia
Related Topics: Asthma Drugs
